XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Ordinary shares
Additional paid-in capital
Accumulated other comprehensive income /(loss)
Accumulated deficit
Total
Beginning balance at Dec. 31, 2022 $ 2,838 $ 1,113,393 $ (58,291) $ (581,931) $ 476,009
Beginning balance (in shares) at Dec. 31, 2022 46,968,032        
Increase (decrease) in shareholders' equity          
Loss for the period       (77,227) (77,227)
Other comprehensive income (loss), net     5,797   5,797
Exercises of share options $ 1 86     87
Exercises of share options (in shares) 10,055        
Restricted and performance share units distributed during the period $ 30 (30)      
Restricted and performance share units distributed during the period (in shares) 566,091        
Share-based compensation expense   8,061     8,061
Issuance of ordinary shares relating to employee stock purchase plan   44     44
Issuance of ordinary shares relating to employee stock purchase plan (in shares) 2,495        
Ending balance at Mar. 31, 2023 $ 2,869 1,121,554 (52,494) (659,158) 412,771
Ending balance (in shares) at Mar. 31, 2023 47,546,673        
Beginning balance at Dec. 31, 2023 $ 2,883 1,148,749 (53,553) (890,409) $ 207,670
Beginning balance (in shares) at Dec. 31, 2023 47,833,830       47,833,830
Increase (decrease) in shareholders' equity          
Loss for the period       (65,618) $ (65,618)
Other comprehensive income (loss), net     (2,489)   (2,489)
Restricted and performance share units distributed during the period $ 36 (36)      
Restricted and performance share units distributed during the period (in shares) 658,527        
Share-based compensation expense   7,191     7,191
Ending balance at Mar. 31, 2024 $ 2,919 $ 1,155,904 $ (56,042) $ (956,027) $ 146,754
Ending balance (in shares) at Mar. 31, 2024 48,492,357       48,492,357